Condition: Healthy Adult Participants · Sponsor: Jiangsu Aidea Pharmaceutical Group Co., Ltd.
A Phase I Study of ADB116 for Injection in Healthy Chinese Adults. This study aims as follows: Primary Objective: • To evaluate the safety and tolerability of a single intravenous bolus dose of ADB116 for injection in healthy Chinese adults. Secondary Objective: • To evaluate the pharmacokinetic (PK) profile of a single intravenous bolus dose of ADB116 for injection.
This description comes directly from the study's public registry record.
Xinmin Yun, Ph.D · ＋86 0514-87752666 · yunxm@aidea.com.cn
Bing Yang, M.Sc · ＋86 025-83193180 · yangbing@aidea.com.cn
Always discuss trial participation with your own doctor first.
| NanFang Hospital of Southern Medical University | Guangzhou, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07729839